MedTrace Logo

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

NCT02688270 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2022-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.

Conditions

  • Raynaud's Phenomenon Secondary to Connective Tissue Disease

Interventions

DRUG

Vascana (0.9% nitroglycerin cream)

Study drug administered topically

DRUG

Vehicle Cream (placebo)

Vehicle administered topically

Sponsors & Collaborators

  • Covis Pharma S.à.r.l.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02688270 on ClinicalTrials.gov